“Cognitive impairments are the worst”: Staff perspectives on challenges in buprenorphine care for people with cognitive and mental health disabilities who inject drugs
Disability and Health Journal · 2027-01 · 20 (1) · 102130
DOI: 10.1016/j.dhjo.2026.102130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disability and Health Journal, 2027-01. Verfasst von Roberto Abadie. Beteiligte Einrichtung: Department of Kinesiology, University of Wisconsin-Madison, 470 N Charter St Suite 205., Madison, WI, 503706, United States. Electronic address: raba…. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Persons with Disabilities, Cognitive Dysfunction. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Opioid use disorder (OUD) is highly prevalent among people with disabilities, who often experience cognitive and mental health impairments. These disabilities can complicate treatment and contribute to disparities in access and outcomes. OBJECTIVE: To explore staff perspectives on cognitive and mental health impairments among people who inject drugs (PWID) receiving buprenorphine treatment, and how these challenges affect care delivery. METHODS: From March 2025 to January 2026, 29 staff members from two buprenorphine clinics in the San Juan metropolitan area of Puerto Rico participated in semi-structured interviews. Data were analyzed using inductive and deductive coding to identify themes related to cognitive and mental health disabilities, treatment barriers, and management strategies. RESULTS: Staff encountered a wide range of cognitive and mental health challenges. Stigmatized severe mental health conditions, such as schizophrenia or bipolar disorder, tended to be hidden by patients, affecting treatment outcomes. Staff viewed severe intellectual disabilities as a barrier to treatment due to the perception that patients with such disabilities could not adhere to the requirements of the cognitive therapy employed by the clinics. Often patients exhibited both cognitive and mental health impairments simultaneously, adding complexity to buprenorphine treatment and erecting new barriers. CONCLUSION: This study identifies cognitive and mental health impairments among PWID in buprenorphine treatment and highlights the challenges they pose for staff. The findings underscore the need for integrated, disability-informed approaches, including systematic screening, continuous assessment, culturally sensitive training, and community engagement and peer support, as well as further research on prevalence, barriers, and treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Kinesiology, University of Wisconsin-Madison, 470 N Charter St Suite 205., Madison, WI, 503706, United States. Electronic address: rabadie@wisc.edu.
Zitieren
APA
Abadie, R. (2027). “Cognitive impairments are the worst”: Staff perspectives on challenges in buprenorphine care for people with cognitive and mental health disabilities who inject drugs. Disability and Health Journal, 20(1), 102130. https://doi.org/10.1016/j.dhjo.2026.102130
Vancouver
Abadie R. “Cognitive impairments are the worst”: Staff perspectives on challenges in buprenorphine care for people with cognitive and mental health disabilities who inject drugs. Disability and Health Journal. 2027;20(1):102130. doi:10.1016/j.dhjo.2026.102130
BibTeX
@article{Abadie2027,
author = {Abadie, Roberto},
title = {“Cognitive impairments are the worst”: Staff perspectives on challenges in buprenorphine care for people with cognitive and mental health disabilities who inject drugs},
journal = {Disability and Health Journal},
year = {2027},
volume = {20},
number = {1},
pages = {102130},
doi = {10.1016/j.dhjo.2026.102130}
}
EUVIMED